Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).

Yabe D, Kawamori D, Seino Y, Oura T, Takeuchi M

Diabetes, obesity & metabolism2 Nov 2022Cited by 43 (Europe PMC)

PMID36184780PMCIDPMC10092154DOI10.1111/dom.14882PepBankPUB-36184780

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, tirzepatide at all doses differed significantly from dulaglutide in the change of postprandial glucose AUC from time zero to 6 h at Week 32.
In plain wordsIn Japanese adults with type 2 diabetes, after a meal test tirzepatide at all doses changed glucose levels differently from dulaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedPostprandial glucose AUC from time zero to 6 h change at Week 32
Study
n = 48
Comparator
Dulaglutide 0.75 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mg, 10 mg or 15 mg once weekly · 32 weeksAs given in this study (human).
Source sentences
Summary
Following a standardized meal test, statistically significant differences in change from baseline in area under the concentration versus time curve from time zero to 6 h after dose for glucose, insulin
3 context sentences(design, population, supporting numbers)
Summary · context
were observed in all tirzepatide treatment arms, except triglycerides at 10 mg, compared with dulaglutide at Week 32.
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478001
02HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, tirzepatide at all doses differed significantly from dulaglutide in the change of postprandial insulin AUC from time zero to 6 h at Week 32.
In plain wordsIn Japanese adults with type 2 diabetes, after a meal test tirzepatide at all doses changed insulin levels differently from dulaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedPostprandial insulin AUC from time zero to 6 h change at Week 32
Study
n = 48
Comparator
Dulaglutide 0.75 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mg, 10 mg or 15 mg once weekly · 32 weeksAs given in this study (human).
Source sentences
Summary
Following a standardized meal test, statistically significant differences in change from baseline in area under the concentration versus time curve from time zero to 6 h after dose for glucose, insulin, glucagon, C-peptide and triglycerides were observed in all tirzepatide treatment arms, except tri…
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478002
03HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, tirzepatide at all doses differed significantly from dulaglutide in the change of postprandial glucagon AUC from time zero to 6 h at Week 32.
In plain wordsIn Japanese adults with type 2 diabetes, after a meal test tirzepatide at all doses changed glucagon levels differently from dulaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedPostprandial glucagon AUC from time zero to 6 h change at Week 32
Study
n = 48
Comparator
Dulaglutide 0.75 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mg, 10 mg or 15 mg once weekly · 32 weeksAs given in this study (human).
Source sentences
Summary
Following a standardized meal test, statistically significant differences in change from baseline in area under the concentration versus time curve from time zero to 6 h after dose for glucose, insulin, glucagon, C-peptide and triglycerides were observed in all tirzepatide treatment arms, except tri…
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478003
04HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, tirzepatide at all doses differed significantly from dulaglutide in the change of postprandial C-peptide AUC from time zero to 6 h at Week 32.
In plain wordsIn Japanese adults with type 2 diabetes, after a meal test tirzepatide at all doses changed C-peptide levels differently from dulaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedPostprandial C-peptide AUC from time zero to 6 h change at Week 32
Study
n = 48
Comparator
Dulaglutide 0.75 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mg, 10 mg or 15 mg once weekly · 32 weeksAs given in this study (human).
Source sentences
Summary
Following a standardized meal test, statistically significant differences in change from baseline in area under the concentration versus time curve from time zero to 6 h after dose for glucose, insulin, glucagon, C-peptide and triglycerides were observed in all tirzepatide treatment arms, except tri…
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478004
05HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, postprandial triglyceride AUC from time zero to 6 h changed significantly differently from dulaglutide at Week 32 with tirzepatide 5 mg and 15 mg, but not 10 mg.
In plain wordsIn Japanese adults with type 2 diabetes, after a meal, triglycerides differed from dulaglutide with tirzepatide 5 mg and 15 mg, not 10 mg.
Peptide
Tirzepatide
Outcome
Direction not reportedPostprandial triglyceride AUC from time zero to 6 h change at Week 32
Study
n = 48
Comparator
Dulaglutide 0.75 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
5 mg, 10 mg or 15 mg once weekly · 32 weeksAs given in this study (human).
Source sentences
Summary
Following a standardized meal test, statistically significant differences in change from baseline in area under the concentration versus time curve from time zero to 6 h after dose for glucose, insulin, glucagon, C-peptide and triglycerides were observed in all tirzepatide treatment arms, except tri…
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478005
06HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, glucose AUC changes differed between dulaglutide and all tirzepatide treatment arms.
In plain wordsIn Japanese patients with diabetes, glucose responses differed between dulaglutide and all tirzepatide treatment arms.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedPostprandial glucose AUC
Study
n = 48
Comparator
Tirzepatide treatment arms
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 32 weeksAs given in this study (human).
Source sentences
Summary
statistically significant differences in change from baseline in area under the concentration versus time curve from time zero to 6 h after dose for glucose, insulin, glucagon, C-peptide and triglycerides were observed in all tirzepatide treatment arms, except triglycerides at 10 mg, compared with d…
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478008
07HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, insulin AUC changes differed between dulaglutide and all tirzepatide treatment arms.
In plain wordsIn Japanese patients with diabetes, insulin responses differed between dulaglutide and all tirzepatide treatment arms.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedPostprandial insulin AUC
Study
n = 48
Comparator
Tirzepatide treatment arms
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 32 weeksAs given in this study (human).
Source sentences
Summary
statistically significant differences in change from baseline in area under the concentration versus time curve from time zero to 6 h after dose for glucose, insulin, glucagon, C-peptide and triglycerides were observed in all tirzepatide treatment arms, except triglycerides at 10 mg, compared with d…
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478009
08HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, glucagon AUC changes differed between dulaglutide and all tirzepatide treatment arms.
In plain wordsIn Japanese patients with diabetes, glucagon responses differed between dulaglutide and all tirzepatide treatment arms.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedPostprandial glucagon AUC
Study
n = 48
Comparator
Tirzepatide treatment arms
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 32 weeksAs given in this study (human).
Source sentences
Summary
statistically significant differences in change from baseline in area under the concentration versus time curve from time zero to 6 h after dose for glucose, insulin, glucagon, C-peptide and triglycerides were observed in all tirzepatide treatment arms, except triglycerides at 10 mg, compared with d…
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478010
09HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, C-peptide AUC changes differed between dulaglutide and all tirzepatide treatment arms.
In plain wordsIn Japanese patients with diabetes, C-peptide responses differed between dulaglutide and all tirzepatide treatment arms.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedPostprandial C-peptide AUC
Study
n = 48
Comparator
Tirzepatide treatment arms
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 32 weeksAs given in this study (human).
Source sentences
Summary
statistically significant differences in change from baseline in area under the concentration versus time curve from time zero to 6 h after dose for glucose, insulin, glucagon, C-peptide and triglycerides were observed in all tirzepatide treatment arms, except triglycerides at 10 mg, compared with d…
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478011
10HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, all tirzepatide doses (5, 10 and 15 mg) resulted in a significant reduction in body fat mass at Week 52.
In plain wordsIn Japanese adults with type 2 diabetes, body fat mass fell significantly at all tirzepatide doses.
Peptide
Tirzepatide
Outcome
DecreaseBody fat mass at Week 52
Study
n = 29
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mg, 10 mg or 15 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
and all doses of tirzepatide resulted in a significant reduction in body fat mass at Week 52.
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478007
11HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, tirzepatide 10 mg and 15 mg resulted in a significant body weight reduction at Week 52.
In plain wordsIn Japanese adults with type 2 diabetes, body weight fell significantly after 52 weeks of tirzepatide 10 mg and 15 mg.
Peptide
Tirzepatide
Outcome
DecreaseBody weight at Week 52
Study
n = 20
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mg, 10 mg or 15 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
For body composition, tirzepatide 10 mg and 15 mg resulted in a significant reduction in body weight
3 context sentences(design, population, supporting numbers)
Summary · context
Tirzepatide reduced body weight and body fat mass.
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478006
12HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, triglyceride AUC changes differed significantly between dulaglutide and tirzepatide, except at 10 mg.
In plain wordsIn Japanese patients with diabetes, triglyceride responses differed significantly between dulaglutide and tirzepatide, except at 10 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedPostprandial triglyceride AUC
Study
n: not reported in source
Comparator
Tirzepatide 5 mg and 15 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
0.75 mg · 32 weeksAs given in this study (human).
Source sentences
Summary
statistically significant differences in change from baseline in area under the concentration versus time curve from time zero to 6 h after dose for glucose, insulin, glucagon, C-peptide and triglycerides were observed in all tirzepatide treatment arms, except triglycerides at 10 mg, compared with d…
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan.
Summary · context
Of 636 participants in SURPASS J-mono, 48 were included in this substudy and assigned to tirzepatide 5 mg (n = 9), tirzepatide 10 mg (n = 11), tirzepatide 15 mg (n = 9), or dulaglutide 0.75 mg (n = 19).
Report a problemFND-3618478012

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).

Summary

Results from this study12

Version history

Subjects

Publication types

MeSH terms

Keywords